Hangzhou Jiayin Biotech Ltd
9
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD
Role: lead
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Role: lead
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
Role: lead
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
Role: lead
A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA
Role: lead
The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
Role: lead
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
Role: lead
Clinical Trial to Evaluate the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy Type I
Role: lead
A Study of EXG102-031 in Participants With wAMD
Role: lead
All 9 trials loaded